His-purkinje system pacing upgrade improve the heart performances in patients suffering from pacing-induced cardiomyopathy with or without permanent atrial fibrillation

Introduction: The efficacy and safety of his-purkinje system pacing (HPSP) upgrades in patients with pacinginduced cardiomyopathy (PICM) and atrial fibrillation (AF) are still unknown. Methods and results: Patients with PICM were continuously enrolled from January 2018 to March 2020. All patients were further divided into AF subgroup and sinus rhythm subgroup. Clinical data including echocardiographic examination parameters, electrocardiogram (ECG) measurements, and New York Heart Association (NYHA) classification, were assessed before and after the procedure. The HPSP upgrades, including his bundle pacing (HBP) and left bundle branch pacing (LBBP) were completed in 34 of 36 (94%) patients, Complications including electrode dislodged, perforation, infection or thrombosis were not observed in the perioperative period. During a mean of 11.52 +/- 5.40 months of follow-up. The left ventricular ejection fraction (LVEF) increased significantly (33.76 +/- 7.54 vs 40.41 +/- 9.06, P < 0.001), and the QRS duration decreased (184.22 +/- 23.76 ms vs 120.52 +/- 16.67 ms, P < 0.001) after the upgrades. LVEDD reversed from 59.29 +/- 7.74 mm to 53.91 +/- 5.92 mm (P < 0.001), and the NYHA functional class also improved to 2.00 +/- 0.76 from 2.55 +/- 0.91 at the first follow-up (P < 0.001). The left atrium (LA) size also slightly decreased compared to the initial state (47.44 +/- 7.14 mm VS 45.56 +/- 7.78, P = 0.010). BNP significantly decreased from a median value of 458.06 (256.35-755.10) to 172.31(92.69-552.14) (P = 0.004). The threshold did not increase significantly (1.18 +/- 0.76 mv@0.4 ms vs 1.26 +/- 0.91mv @ 0.4 ms, P = 0.581). These improvements in patients with AF were similar with those in patients without AF (P > 0.05). Conclusions: HPSP upgrades improved the heart performance and reversed the left ventricular remodeling in patients suffering from PICM with or without AF, and it should be a promising choice in these patients. (C) 2021 Published by Elsevier B.V.

Automated summary

HPSP upgrades improved heart performance and reversed left ventricular remodeling in patients with PICM, whether they have AF or not. The treatment showed promising results in improving clinical outcomes.